Dejan M Opsenica
Overview
Explore the profile of Dejan M Opsenica including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matosevic A, Opsenica D, Bartolic M, Marakovic N, Stoilkovic A, Komatovic K, et al.
Molecules
. 2024 Nov;
29(22).
PMID: 39598746
As some previously reported studies have proven that amodiaquine, in addition to its primary antimalarial activity, also has potential for new applications such as the inhibition of cholinesterases, in our...
2.
Matosevic A, Opsenica D, Spasic M, Marakovic N, Zandona A, Zunec S, et al.
Chem Biol Interact
. 2023 Jul;
382:110620.
PMID: 37406982
The most successful therapeutic strategy in the treatment of Alzheimer's disease (AD) is directed toward increasing levels of the neurotransmitter acetylcholine (ACh) by inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE),...
3.
Komatovic K, Matosevic A, Terzic-Jovanovic N, Zunec S, Segan S, Zlatovic M, et al.
Pharmaceutics
. 2022 Jun;
14(6).
PMID: 35745878
Considering that acetylcholinesterase (AChE) inhibition is the most important mode of action expected of a potential drug used for the treatment of symptoms of Alzheimer's disease (AD), our previous pilot...
4.
Aleksic I, Jeremic J, Milivojevic D, Ilic-Tomic T, Segan S, Zlatovic M, et al.
ACS Chem Biol
. 2019 Oct;
14(12):2800-2809.
PMID: 31647218
is a leading cause of nosocomial infections that are becoming increasingly difficult to treat due to the occurrence of antibiotic resistant strains. Since virulence is controlled through quorum sensing, small...
5.
Bosak A, Opsenica D, Sinko G, Zlatar M, Kovarik Z
Chem Biol Interact
. 2019 May;
308:101-109.
PMID: 31100281
Eight derivatives of 4-aminoquinolines differing in the substituents attached to the C(4)-amino group and C(7) were synthesised and tested as inhibitors of human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Both enzymes...
6.
Aleksic I, Segan S, Andric F, Zlatovic M, Moric I, Opsenica D, et al.
ACS Chem Biol
. 2017 Mar;
12(5):1425-1434.
PMID: 28350449
Antibiotic resistance has become a serious global threat to public health; therefore, improved strategies and structurally novel antimicrobials are urgently needed to combat infectious diseases. Here we report a new...
7.
Videnovic M, Opsenica D, Burnett J, Gomba L, Nuss J, Selakovic Z, et al.
J Med Chem
. 2014 Apr;
57(10):4134-53.
PMID: 24742203
Significantly more potent second generation 4-amino-7-chloroquinoline (4,7-ACQ) based inhibitors of the botulinum neurotoxin serotype A (BoNT/A) light chain were synthesized. Introducing an amino group at the C(3) position of the...
8.
Cvijetic I, Zizak Z, Stanojkovic T, Juranic Z, Terzic N, Opsenica I, et al.
Eur J Med Chem
. 2010 Aug;
45(10):4570-7.
PMID: 20705369
An alignment-free 3D QSAR study on antiproliferative activity of the thirty-three 1,2,4,5-tetraoxane derivatives toward two human dedifferentiated cell lines was reported. GRIND methodology, where descriptors are derived from GRID molecular...
9.
Opsenica D, Terzic N, Smith P, Yang Y, Anova L, Smith K, et al.
Bioorg Med Chem
. 2008 Jun;
16(14):7039-45.
PMID: 18550377
Eleven new tetraoxanes possessing cholic acid-derived carrier and isopropylidene moiety were synthesized and were tested in vitro and in vivo. In vitro screening revealed that nine of them were more...